 SEATTLE, Jan. 06, 2021 GLOBE NEWSWIRE -- Atossa Therapeutics, Inc. Nasdaq: ATOS the Company or Atossa, a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of significant unmet medical need with a current focus on breast cancer and COVID-19, announced today that it has entered into a securities purchase agreement with institutional investors to purchase 25.2 million of its shares of common stock and warrants in a registered direct offering priced at-the-market under Nasdaq rules. The combined purchase price for one share of common stock and .75 warrants to purchase one share of common stock is 1.055. 